It is estimated that in Spain this type of medication has achieved an estimated saving of some €5.162 million between 2009 and 2022. However, Spain is one of the countries with the slowest and lowest rate of adoption of this type of treatment. They are data offered during the course of the day 'CHANGE: Consensus and Agreements on Biosimilar Medicines', organized by Biogen.
recently published
Horizon scanning
Jan 31 2024
Early Treatment: the role of biosimilars
18 2023 December
